The boss of US pharmaceutical giant Eli Lilly says there is no looking back from Donald Trump's decision to impose sweeping tariffs on imports from the rest of the world. In an exclusive interview with the BBC,

Lilly, a sweet and social 1-year-old old terrier with a lot of positive qualities, is available for adoption at The Cat House on the Kings.

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated 1.4 billion people worldwide, including 64 million people in the U.S.

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the biotech's neurotropic adeno-associated virus capsid in efforts to develop a | Sangamo Therapeutics has secured a licensing deal with Eli Lilly that helps extend the cash-strapped company’s runway.

As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aiming for a slam dunk of its own. | As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aiming for a slam dunk of its own.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 agonists could be evolving, and Eli Lilly has a high-stakes opportunity to dominate it over the coming year.

Combination treatment with a GLP-1 agonist and thiazolidinedione in type 2 diabetes was tied to a significantly lower risk of all-cause mortality, major adverse cardiovascular events, and cardiovascular mortality compared with use of neither of the agents, according to a large cohort study. ( JAMA Network Open)